MDT

100.82

-0.34%↓

A

136.42

-1.99%↓

VEEV

224.05

-0.25%↓

HQY

84.52

-0.8%↓

NEOG

9.9

-1.2%↓

MDT

100.82

-0.34%↓

A

136.42

-1.99%↓

VEEV

224.05

-0.25%↓

HQY

84.52

-0.8%↓

NEOG

9.9

-1.2%↓

MDT

100.82

-0.34%↓

A

136.42

-1.99%↓

VEEV

224.05

-0.25%↓

HQY

84.52

-0.8%↓

NEOG

9.9

-1.2%↓

MDT

100.82

-0.34%↓

A

136.42

-1.99%↓

VEEV

224.05

-0.25%↓

HQY

84.52

-0.8%↓

NEOG

9.9

-1.2%↓

MDT

100.82

-0.34%↓

A

136.42

-1.99%↓

VEEV

224.05

-0.25%↓

HQY

84.52

-0.8%↓

NEOG

9.9

-1.2%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

20.71 1.57

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.35

Max

20.82

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

89.037

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-7% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.18%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

42M

410M

Iepriekšējā atvēršanas cena

19.14

Iepriekšējā slēgšanas cena

20.71

Ziņu noskaņojums

By Acuity

31%

69%

99 / 360 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. janv. 21:55 UTC

Peļņas

Capital One Financial Posts Higher 4Q Profit As Lending Increases

2026. g. 22. janv. 23:52 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

2026. g. 22. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

2026. g. 22. janv. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Profit-Taking -- Market Talk

2026. g. 22. janv. 23:40 UTC

Tirgus saruna

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

2026. g. 22. janv. 23:30 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. janv. 23:30 UTC

Tirgus saruna

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

2026. g. 22. janv. 22:37 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

2026. g. 22. janv. 21:59 UTC

Iegādes, apvienošanās, pārņemšana

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

2026. g. 22. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. janv. 21:44 UTC

Peļņas

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

2026. g. 22. janv. 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

2026. g. 22. janv. 21:31 UTC

Iegādes, apvienošanās, pārņemšana

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

2026. g. 22. janv. 21:31 UTC

Iegādes, apvienošanās, pārņemšana

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

2026. g. 22. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

2026. g. 22. janv. 21:30 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

2026. g. 22. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Capital One To Acquire Brex >COF

2026. g. 22. janv. 21:13 UTC

Peļņas

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

2026. g. 22. janv. 21:11 UTC

Peļņas

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

2026. g. 22. janv. 21:11 UTC

Peļņas

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

2026. g. 22. janv. 21:10 UTC

Peļņas

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

2026. g. 22. janv. 21:06 UTC

Peļņas

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q Rev $15.58B >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q EPS $3.26 >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q Net Interest Margin 8.26% >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q Net $2.13B >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q Adj EPS $3.86 >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Capital One 4Q Net Charge-Offs $3.8B >COF

2026. g. 22. janv. 21:05 UTC

Peļņas

Intuitive Surgical 4Q EPS $2.21 >ISRG

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-7% uz leju

Prognoze 12 mēnešiem

Vidējais 19 USD  -7%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

99 / 360 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat